Before this page recommends a single milligram of anything, one question: are you taking dexamethasone? Because if your insomnia started with chemotherapy, there is a strong chance the culprit is printed on your own medication schedule. Dexamethasone rides along with most infusion regimens as an anti-nausea drug, it is a potent stimulating steroid, and it wrecks sleep for a large share of the people who take it. No gummy on this site out-argues a steroid dosed at the wrong time of day. The single highest-yield insomnia intervention for a chemo patient is a five-minute conversation with the oncology team about steroid timing, and it costs nothing.
The sleep-product industry will not tell you that, because "talk to your doctor about your dex schedule" doesn't come in elderberry flavor.
With that on the table, cannabinoids do have a real place here. Treatment-related insomnia is rarely one problem. It's steroids plus nighttime nausea plus pain plus the 3am dread that arrives on its own schedule, and the pieces respond to different things. This page covers the pieces where edibles earn their spot.
What broke your sleep determines what helps
Insomnia during treatment splits roughly into trouble falling asleep and trouble staying asleep, and the distinction matters more here than for almost any other population, because the causes map onto it. Steroid activation and anticipatory anxiety mostly attack sleep onset. Nausea, pain, night sweats from endocrine therapy, and the general fragility of medicated sleep mostly attack maintenance, waking you at 2am and 4am and 5:30am.
We cover that split in full on the sleep onset and sleep maintenance pages: low-dose THC shortens the time to fall asleep, CBN's evidence points specifically at staying asleep. Both transfer to the oncology setting with an honest caveat attached, which is that neither has been tested in a randomized trial of cancer patients. Everything below is extrapolated from general sleep research plus observational reports from oncology clinics. That is thinner ground than our cancer pain page stands on, and you deserve to know it.
If nighttime nausea is the thing waking you, stop reading this page and read chemotherapy-induced nausea first. Treating the nausea usually fixes the sleep, and the dosing logic there is different.
The CBN evidence, sized correctly
CBN spent years as the "sleep cannabinoid" on the strength of vibes and one misread 1970s study. It now has actual trial data, and the results are narrower and more interesting than the marketing. A placebo-controlled trial of 293 poor sleepers found that 20mg of CBN nightly reduced nighttime awakenings and overall sleep disturbance. It did nothing for sleep onset latency, and adding CBD to the CBN made it no better. A separate 2024 randomized trial tested CBN doses from 25 to 100mg against 4mg of melatonin and found every group improved about equally, which reads as CBN performing at roughly melatonin strength. Useful. Not a sedative-hypnotic. Melatonin-tier, aimed at the middle of the night rather than the start.
For a chemo patient whose pattern is fragmented sleep, that profile is actually a decent match. For a patient lying awake at midnight with steroid eyes, it is the wrong tool entirely.
Now the label math, because this is where the market gets cheeky. The studied dose was 20mg. Wyld's Elderberry CBN gummy, probably the category's best seller, contains 5mg CBN with 2mg THC per piece at around $28 a bag. Kiva's Camino Midnight Blueberry runs 5mg THC to 1mg CBN, a ratio built backwards for maintenance insomnia and better understood as an onset product wearing nighttime packaging. 1906's Midnight comes closest to a sensible split at 5mg and 5mg. Nothing on the mainstream shelf delivers the trial dose in one piece, and nobody's packaging mentions that.
THC, in this population specifically
Low-dose THC (2.5 to 5mg) shortens sleep onset and adds sedation that many patients on active treatment genuinely appreciate. Two cautions carry extra weight here. Tolerance to the sleep effect builds within weeks of nightly use, faster than most people expect, and a dose escalation habit is a bad fit for someone whose drug list is already long. And higher THC doses degrade sleep quality even as they knock you out, trading a faster start for worse architecture. During treatment, when sleep is doing actual repair work, that trade is worse than usual. Start at 2.5mg, treat 5mg as the ceiling, and take nights off when symptoms allow.
The dexamethasone interaction, and the sedation stack
This section is the reason the oncology conversation is mandatory rather than polite.
Dexamethasone is processed by CYP3A4, the same liver enzyme family that handles THC and CBD, and CBD in particular inhibits it at meaningful doses. Altering how your body clears a steroid that your regimen depends on is not a variable to introduce silently. The interaction list extends past dex: many targeted therapies, anti-emetics, and anticoagulants run through the same pathways, which is the standing theme across cannabis use in oncology and the reason blanket reassurance from a dispensary counter is worth what you paid for it.
Separately, sedation stacks. Cannabinoids plus opioids, plus benzodiazepines, plus prescription sleep aids like zolpidem, compound into next-morning grogginess at best and a fall risk at worst, in a population where a fall matters. If you are on any of those, the edible conversation happens with the prescriber first.
None of this means no. Palliative care teams in legal states navigate exactly this daily and mostly say yes with adjustments. It means the sequence is fixed: team first, gummy second.
What to actually buy, and when not to buy anything
For maintenance-pattern insomnia: a CBN-forward product dosed honestly against the 20mg trial figure, which in practice means two to four pieces of most retail products, so do the per-milligram price math before committing to a brand. For onset-pattern insomnia: 2.5mg THC, evening only, with the tolerance warning above taken seriously. For steroid-pattern insomnia, the wide-awake-at-1am-feeling-electric kind: save your money and make the phone call, because that pattern belongs to the dexamethasone conversation and no shelf product wins it.
Dispensary product with a third-party COA only. The mail-order hemp market is shutting down in phases this fall and winter, its supply chain is degrading on the way out, and untested synthesized cannabinoids were never a reasonable input for an immunocompromised body in the first place.
The closing insight: in oncology, insomnia is usually a symptom wearing a diagnosis costume. The gummy aisle treats it as the disease itself, because that's what the gummy aisle sells. Find the cause, fix what's fixable with your team, and let cannabinoids do the smaller, real job of smoothing what remains.